Stay updated with breaking news from Slides Today. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2022,...
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2022, including sales of...
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2021,...
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Rigel Reports First Quarter 2021 Financial Results and Provides Business Update - Reported positive topline results of fostamatinib in Phase 2 clinical trial in hospitalized patients with COVID-19 - Net product sales of $12.4 million and total revenues of $81.0 million - Received upfront cash payment of $125 million from Eli Lilly for the exclusive license agreement for Rigel's RIP1 inhibitor program - Conference call and webcast today at 4:30PM Eastern Time News provided by Share this article Share this article SOUTH SAN FRANCISCO, Calif., May 5, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, ...